3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
The post 3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge appeared first on InvestorPlace.
Uncategorized
Active Pharmaceutical Ingredient Market Trends Signal Growth Towards USD 446.6 Billion by 2032 With CAGR AT 6.4%
Active Pharmaceutical Ingredient Market Insights, Developments, and Key Players Shaping the Growth Trajectory of the API MarketNew York, April 23, 2024 (GLOBE NEWSWIRE) — Overview According to Dimension Market Research,
Takeda Pharmaceutical: A Long-Term Cash Cow
Takeda Pharmaceutical Co. Ltd. ( NYSE:TAK) is the largest Japanese pharmaceutical company and holds a leading position in the global immunoglobulins market.
Biomarin Pharmaceutical earnings preview: what Wall Street is expecting
Biomarin Pharmaceutical will report earnings from Q1.Wall Street analysts predict earnings per share of $0.320.Go here to track
The 9th Annual GCC Pharmaceutical Regulatory Affairs Summit 2024: Top Experts Convene on GCC Pharma Regulations & Innovations
Themed “Navigate Pharma Regulations with ease & Amplify Commercial Success”, pharmaceutical regulatory authorities and industry leaders convened at the 9th Annual GCC Pharmaceutical Regulatory Affairs Summit in Mövenpick Grand Al Bustan – Dubai,
Pharmaceutical Lactose Market Momentum: Advancing Towards US$ 392.3 Million by 2033, Averaging 5.8% CAGR
According to Future Market Insights’ latest analysis, the global pharmaceutical lactose market size is expected to reach US$ 222.6 million in 2023 and further expand at 5.8% CAGR throughout the forecast period (2023 to 2033).
Nexus Pharmaceuticals sells Pleasant Prairie facility to pharmaceutical giant Eli Lilly
Nexus Pharmaceuticals has sold its Pleasant Prairie manufacturing facility to pharmaceutical giant Eli Lilly and Company for an undisclosed price.
DOH warns medical professionals against receiving gifts, grants or any form of compensation from pharmaceutical companies
The Department of Health (DOH) on Monday issued Department Circular No. 2024- 0141 reminding all medical professionals to “uphold professional and ethical standards” following the recent reports of pharmaceutical companies giving privileges using a “multi-level marketing scheme” to entice them to advertise/prescribe medical products.
Top pharmaceutical company evaluates Optimer for precision liver medicine
The Optimer delivery vehicle was developed to selectively target cells linked to fibrotic liver disease, as part of a fee-for-service partnership with the pharmaceutical company that began in 2020. Subsequent work at Aptamer Group combining the Optimer with a model gene therapy payload has shown that the Optimer enables selective delivery of the gene therapy
Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?
West Pharmaceutical Services WST is scheduled to release first-quarter 2024 results on Apr 25, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 2.81%.